Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridging Study of Non-Adjuvanted H1N1 Vaccine in India
NCT01053143Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2010
- Primary completion
- Aug 2010
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Influenza A (H5N1) virus vaccine in influenza A H1N1 infection (H1N1), sponsored by Sanofi. Primary endpoints: Safety profile (injection site reactions and systemic events) at 21 days and Serious Adverse Events at 6 months. Started Jan 2010; status: completed.
02
Drugs
Influenza A (H5N1) virus vaccine
03
Conditions
influenza A H1N1 infection (H1N1)
Beyond the preview
Go deeper on NCT01053143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01053143.